Aurora Cannabis Inc.

Aurora Cannabis Inc.

May 31, 2016 07:30 ET

RETRANSMISSION: Aurora Cannabis Exceeds 3,000 Active Registered Patients in Five Months

Production, Inventory and Customer Care Meeting Rising Demand

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 31, 2016) - Aurora Cannabis Inc. (CSE:ACB)(FRANKFURT:21P)(WKN:A1C4WM)(OTCQB:ACBFF) ("Aurora" or the "Company"), announced that the Company has exceeded 3,000 active registered patients over the first five months since commencement of product sales on January 5, 2016. Management believes this is the fastest organic rate of growth in patient registration that any Licensed Producer has achieved, and will help the Company towards reaching profitability in record time.

The Company previously announced on March 31, 2016 that it had registered 1,000 patients in its first three months of product sales, and on May 9, 2016 that it had surpassed 2,000 patients over its first four months of sales.

"Aurora's pace of patient acquisition is unprecedented in the industry, and has exceeded our expectations," said Terry Booth, CEO. "We had optimistically planned for this high rate of growth, and I'm proud that our cannabis production and inventory, as well as our customer care team, continue to manage this increasing demand very well. Our customer retention rate thus far exceeds 90%, and we will continue to be diligent in ensuring that we onboard patients at a pace we can accommodate as we continue to scale up. At the same time, we will ensure our patients remain completely satisfied with Aurora's medical cannabis and their overall customer care experience is aligned with the Aurora Standard."

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol "ACB".

On behalf of the Board of Directors,


Terry Booth, CEO

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

Contact Information